Core Viewpoint - The stock price of Te Yi Pharmaceutical has shown significant growth this year, with a year-to-date increase of 56.84% and a recent surge of 14.52% over the last five trading days [2] Group 1: Stock Performance - As of November 27, Te Yi Pharmaceutical's stock price rose by 2.57% to 13.96 CNY per share, with a trading volume of 8.83 billion CNY and a turnover rate of 17.18%, resulting in a total market capitalization of 71.62 billion CNY [1] - The company has appeared on the stock market's "Dragon and Tiger List" 12 times this year, with the most recent appearance on November 26, where it recorded a net buy of -19.39 million CNY [2] Group 2: Financial Performance - For the period from January to September 2025, Te Yi Pharmaceutical achieved a revenue of 6.92 billion CNY, reflecting a year-on-year growth of 51.86%, while the net profit attributable to shareholders reached 65.22 million CNY, marking an impressive increase of 985.18% [2] - The company has distributed a total of 10.59 billion CNY in dividends since its A-share listing, with 3.56 billion CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2] - Among the top ten circulating shareholders, the third-largest is the Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A, holding 3.33 million shares, while the fourth is the Xingquan Hu-Shen 300 Index Enhanced A, holding 1.92 million shares, both unchanged from the previous period [3]

Core Viewpoint - The stock of Te Yi Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 35.94%, indicating volatility in its market performance [1]. Company Performance - As of September 30, 2025, Te Yi Pharmaceutical reported a revenue of 6.92 billion yuan, representing a year-on-year growth of 51.86%, and a net profit attributable to shareholders of 652.17 million yuan, which is a significant increase of 985.18% compared to the previous year [2]. - The company has distributed a total of 1.059 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]. Stock Market Activity - The stock price of Te Yi Pharmaceutical is currently at 12.10 yuan per share, with a trading volume of 2.60 billion yuan and a turnover rate of 5.62%, leading to a total market capitalization of 6.207 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 17, where it recorded a net buy of -733.44 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2]. - Among the top ten circulating shareholders, notable positions include the "Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A" and "Xingquan Hu-Shen 300 Index Enhanced (LOF) A," which maintained their holdings [3].

Core Viewpoint - On October 20, Te Yi Pharmaceutical experienced a 5.3% increase in stock price, reaching 9.34 CNY per share, with a trading volume of 145 million CNY and a turnover rate of 4.26%, resulting in a total market capitalization of 4.788 billion CNY [1] Company Overview - Te Yi Pharmaceutical Group Co., Ltd. is located in Taicheng, Guangdong Province, and was established on May 23, 2002, with its listing date on July 31, 2014 [1] - The company's main business involves the research, development, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials [1] - The revenue composition of the company is as follows: Traditional Chinese medicine 61.00%, chemical preparations 32.61%, chemical raw materials 5.77%, and chemical products and others 0.61% [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds a significant position in Te Yi Pharmaceutical [2] - GF Xinhe Mixed A (004750) held 246,200 shares in the second quarter, accounting for 0.21% of the fund's net value, ranking as the tenth largest heavy stock [2] - The estimated floating profit for today is approximately 115,700 CNY [2] - GF Xinhe Mixed A was established on January 16, 2018, with a latest scale of 171 million CNY, and has achieved a year-to-date return of 3.42% [2] - The fund manager, Wu Di, has a tenure of 5 years and 168 days, with a total asset scale of 77.42 billion CNY [2]